Recurrent ERBB2 alterations are associated with esophageal adenocarcinoma brain metastases.
Lawson NM. et al, (2025)
Open-label, phase Ia study of STING agonist BI 1703880 plus ezabenlimab for patients with advanced solid tumors.
Harrington K. et al, (2025), Future Oncol, 21, 195 - 200
Redefining PD1 as a guardian of stem-like T cells.
Jackson M. and Parkes EE., (2024), Nat Rev Immunol
Validity and timeliness of cancer diagnosis data collected during a prospective cohort study and reported by the English and Welsh cancer registries: a retrospective, comparative analysis.
Jackson A. et al, (2024), Lancet Oncol, 25, 1476 - 1486
A retrospective analysis of the validity and timeliness of cancer diagnosis data collected during a prospective cohort study and reported by the English and Welsh cancer registries
Jackson A. et al, (2024), The Lancet Oncology
Targeting mitotic regulators in cancer as a strategy to enhance immune recognition.
Gregorczyk M. and Parkes EE., (2023), DNA Repair (Amst), 132
STAT3/LKB1 controls metastatic prostate cancer by regulating mTORC1/CREB pathway.
Pencik J. et al, (2023), Mol Cancer, 22
Non-cell-autonomous cancer progression from chromosomal instability.
Li J. et al, (2023), Nature, 620, 1080 - 1088
cGAS-STING signalling in cancer: striking a balance with chromosomal instability.
Beernaert B. and Parkes EE., (2023), Biochem Soc Trans
Investigating the effects of homologous recombination deficiency on radiotherapy response in pre-clinical prostate cancer
Kwon J. et al, (2023), EUROPEAN UROLOGY, 83
Phase I, first-in-human trial evaluating the STING agonist BI 1387446 alone and in combination with ezabenlimab in solid tumors
Calvo E. et al, (2023), ANNALS OF ONCOLOGY, 34, S626 - S626
A non-coding RNA balancing act: miR-346-induced DNA damage is limited by the long non-coding RNA NORAD in prostate cancer.
Fletcher CE. et al, (2022), Mol Cancer, 21
When breaks get hot: inflammatory signaling in BRCA1/2-mutant cancers.
van Vugt MATM. and Parkes EE., (2022), Trends Cancer, 8, 174 - 189
Activation of a cGAS-STING-mediated immune response predicts response to neoadjuvant chemotherapy in early breast cancer.
Parkes EE. et al, (2022), Br J Cancer, 126, 247 - 258
A multi-arm, phase 2, open-label study to assess the efficacy of RXC004 as monotherapy and in combination with nivolumab in patients with ring finger protein 43 (RNF43) or R-spondin (RSPO) aberrated, metastatic, microsatellite stable colorectal cancer following standard treatments
Kopetz S. et al, (2022), JOURNAL OF CLINICAL ONCOLOGY, 40
Chromosomal instability shapes the tumor microenvironment through a chronic ER-stress response
Li J. et al, (2022), CANCER RESEARCH, 82